Fox Run Management, L.L.C. Celldex Therapeutics, Inc. Transaction History
Fox Run Management, L.L.C.
- $553 Million
- Q2 2025
A detailed history of Fox Run Management, L.L.C. transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Fox Run Management, L.L.C. holds 19,146 shares of CLDX stock, worth $529,769. This represents 0.07% of its overall portfolio holdings.
Number of Shares
19,146
Previous 32,670
41.4%
Holding current value
$529,769
Previous $592,000
34.29%
% of portfolio
0.07%
Previous 0.1%
Shares
6 transactions
Others Institutions Holding CLDX
# of Institutions
202Shares Held
68.3MCall Options Held
219KPut Options Held
238K-
Kynam Capital Management, LP Princeton, NJ6.1MShares$169 Million14.83% of portfolio
-
Wellington Management Group LLP Boston, MA5.23MShares$145 Million0.02% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$130 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.96MShares$109 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.82MShares$106 Million0.01% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.29B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...